Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct 19;9(11):e0862.
doi: 10.1002/rcr2.862. eCollection 2021 Nov.

Lung transplantation for post-COVID-19 pulmonary fibrosis

Pratibha Gogia  1 , Sandeep Attawar  2 , Vivek Singh  2 , Tarun Bhatnagar  1 , Sanjay Sharma  1 , Khushboo Batra  1 , Swapnil Khare  1
Affiliations
Case Reports

Lung transplantation for post-COVID-19 pulmonary fibrosis

Pratibha Gogia et al. Respirol Case Rep. .

Abstract

COVID-19 has affected over a billion people around the world, with over 2 million losing their lives (Worldometer). About 10% of patients infected with COVID-19 develop a serious illness, including respiratory failure, that require advanced life-supporting measures. Mortality among this subgroup exceeds 60%. We present a case of an otherwise healthy 34-year-old male who developed end-stage pulmonary fibrosis following COVID-19 infection. He achieved haemodynamic stability with mechanical ventilation and extracorporeal membrane oxygenation (ECMO) but did not show any sign of weaning off ECMO; however, he successfully underwent bilateral lung transplantation.

Keywords: COVID‐19; adult respiratory distress syndrome; extracorporeal membrane oxygenation; lung transplantation; pulmonary fibrosis.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

FIGURE 1
FIGURE 1
(A–D) Chest x‐ray and computed tomography of the thorax done on the day the patient was tested COVID positive (27 September)
FIGURE 2
FIGURE 2
(A–D) Chest x‐ray and computed tomography of the thorax after almost a month of COVID‐positive report (24 October)
FIGURE 3
FIGURE 3
Post‐transplant chest x‐ray
FIGURE 4
FIGURE 4
Timeline
See this image and copyright information in PMC

References

    1. Remuzzi A, Remuzzi G. COVID‐19 and Italy: what next? Lancet. 2020;395:1225–8. - PMC - PubMed
    1. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81. - PMC - PubMed
    1. Scavone C, Brusco S, Bertini M. Current pharmacological treatments for COVID‐19: what's next? Br J Pharmacol. 2020. Nov;177(21):4813–24. 10.1111/bph.15072 - DOI - PMC - PubMed
    1. McMahon JH, Udy A, Peleg AY. Remdesivir for the treatment of Covid‐19 –preliminary report. N Engl J Med. 2020. Sep 3;383(10):992–3. 10.1056/NEJMc2022236 - DOI - PubMed
    1. The RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with Covid‐19 – preliminary report. N Engl J Med. 2020;384(8):693–704. 10.1056/NEJMoa2021436 - DOI - PMC - PubMed

Publication types

LinkOut - more resources